Prostate was radiated in 2021 and pelvic node and pelvis in 2023. Cancer is growing prostate, shrinking in pelvic node, and spread to an abdominal node. Opinions are welcome on two subjects.
I have started on ADT Orgovyx with no side effects in a month. The urologist plans to add an ARI (reception inhibitor)) and I prefer Nubeqa (darolutamide) which has less risk of seizure because it does not cross the blood brain barrier. However, I now read that darolutamide “inhibits the BCRP transporter so its concomitant use with BCRP substrates such as rosuvastatin, should be avoided where possible.” And of all the statins, I have been taking rosuvastatin, specifically because like darolutamide, it does not cross that barrier. So is darolutamide with rosuvastatin good because they both don’t cross the barrier, or bad because one inhibits the other? Should I change my statin to simvastatin, or choose the ARI to be Erleada (apalutamide)?
He also proposes adding Prolia (desunamab) to head off bone loss. He does not want to do a DEXA bone density test first because it would show no bone loss yet, which might prevent approval of Prolia. But I am a little afraid of Prolia’s side effects and wonder if calcium pills and weight bearing exercise will make it unnecessary. Should I take Prolia now, or wait to see what a DEXA scan shows in 6 months?